Barclays’s Clearside Biomedical CLSD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-14
| Closed | -$56 | – | 5301 |
|
|
2025
Q3 | $56 | Buy |
+14
| New | +$95 | ﹤0.01% | 5303 |
|
|
2022
Q1 | – | Sell |
-33
| Closed | -$1K | – | 5021 |
|
|
2021
Q4 | $1K | Sell |
33
-1,104
| -97% | -$71.5K | ﹤0.01% | 4064 |
|
|
2021
Q3 | $102K | Buy |
+1,137
| New | +$100K | ﹤0.01% | 3895 |
|
|
2021
Q2 | – | Sell |
-1,136
| Closed | -$42K | – | 4892 |
|
|
2021
Q1 | $42K | Buy |
+1,136
| New | +$57K | ﹤0.01% | 4237 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 6166 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 6390 |
|
|
2019
Q3 | – | Sell |
-2,425
| Closed | -$34.8K | – | 6746 |
|
|
2019
Q2 | $35K | Buy |
2,425
+1,867
| +335% | +$33.3K | ﹤0.01% | 6236 |
|
|
2019
Q1 | $12K | Buy |
558
+346
| +163% | +$6.87K | ﹤0.01% | 6507 |
|
|
2018
Q4 | $3K | Sell |
212
-1,115
| -84% | -$52.3K | ﹤0.01% | 6592 |
|
|
2018
Q3 | $122K | Buy |
1,327
+893
| +206% | +$106K | ﹤0.01% | 5379 |
|
|
2018
Q2 | $70K | Sell |
434
-76
| -15% | -$12.8K | ﹤0.01% | 5459 |
|
|
2018
Q1 | $82K | Buy |
510
+283
| +125% | +$34.5K | ﹤0.01% | 5525 |
|
|
2017
Q4 | $24K | Buy |
227
+195
| +609% | +$20.9K | ﹤0.01% | 6202 |
|
|
2017
Q3 | $4K | Buy |
32
+21
| +191% | +$2.56K | ﹤0.01% | 6468 |
|
|
2017
Q2 | $1K | Sell |
11
-15
| -58% | -$1.8K | ﹤0.01% | 6495 |
|
|
2017
Q1 | $3K | Sell |
26
-227
| -90% | -$26.8K | ﹤0.01% | 6377 |
|
|
2016
Q4 | $33K | Buy |
+253
| New | +$63.5K | ﹤0.01% | 5386 |
|
Other funds holding CLSD
Barclays's CLSD Position: Q4 2025 in Review
Barclays sold out of Clearside Biomedical (CLSD) in Q4 2025, closing a stake of 14 shares — an estimated $56 sold.
Barclays first reported a position in CLSD in Q4 2016 and held it in 15 quarters. The position peaked at $122K in Q3 2018. 1 fund tracked by Wall St. Rank holds CLSD as of Q4 2025.
- Barclays reported no remaining Clearside Biomedical position as of Q4 2025 after selling out during the quarter.
- Barclays sold 14 Clearside Biomedical shares in Q4 2025, an estimated $56.
- Barclays first reported a position in Clearside Biomedical in Q4 2016 and held it in 15 quarters.
- Barclays's Clearside Biomedical position peaked at $122K in Q3 2018.
- 1 fund tracked by Wall St. Rank held Clearside Biomedical as of Q4 2025.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.